Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
The trial will assess the addition of stereotactic ablative radiotherapy (SABR) to standard anti-cancer therapy (SACT) in patients with oligometastatic non-small cell lung cancer. Patients will be randomised to receive either standard treatment alone (SACT) or standard treatment with conventional radiotherapy (RT) and SABR.
Epistemonikos ID: 95b277033eefe02df02642d463b73e31c90f91ac
First added on: May 12, 2024